Verve Therapeutics, Inc.
Verve Therapeutics, Inc. is a clinical-stage company developing single-course in vivo gene editing medicines to treat atherosclerotic cardiovascular disease by permanently disrupting liver-expressed genes. It develops LNP-encapsulated mRNA and guide RNA therapies—including lead programs VERVE-102/101 targeting PCSK9, VERVE-201 targeting ANGPTL3, and VERVE-301 targeting LPA—using base editing and proprietary GalNAc-LNP delivery. Business activities comprise discovery, preclinical and clinical development, delivery platform optimization, manufacturing partnerships and collaborations. Verve conducts international clinical trials, relies on CMOs for GMP manufacturing and pursues global collaborations and commercialization pathways.
Summary from filing dated 2025-02-27
Frequently asked questions
What is Verve Therapeutics, Inc.'s CIK number?
Verve Therapeutics, Inc.'s SEC CIK number is 0001840574 (1840574). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Verve Therapeutics, Inc.'s SEC filings?
All of Verve Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.